SCHEDULE 13G/A: Rubric Capital Management and David Rosen Maintain Significant Stake in Kiniksa Pharmaceuticals

Rubric Capital Management LP and David Rosen have disclosed a continued beneficial ownership of 8.05% of Kiniksa Pharmaceuticals International, plc's Class A Ordinary Shares.

Summary

• Rubric Capital Management LP and David Rosen, collectively referred to as the Reporting Persons, beneficially own 3,383,239 Class A Ordinary Shares of Kiniksa Pharmaceuticals International, plc.
• This ownership represents 8.05% of the Class A Ordinary Shares outstanding.
• The percentage is based on 42,009,500 Class A Ordinary Shares outstanding as of February 21, 2025, as reported in Kiniksa's Annual Report on Form 10-K for the year ended December 31, 2024.
• Rubric Capital Management LP acts as the investment adviser to investment funds and/or accounts (Rubric Funds) that hold these shares.
• David Rosen is the Managing Member of Rubric Capital Management GP LLC, the general partner of Rubric Capital.
• The Reporting Persons share both voting and dispositive power over the 3,383,239 shares.
• The filing is an Amendment No. 2 to a Schedule 13G, indicating an update to a previously filed beneficial ownership statement.

Sentiment

Score: 5

Explanation: The document is a factual disclosure of beneficial ownership and does not contain information that would inherently suggest a positive or negative sentiment regarding the company's operational or financial performance.

Positives

• The continued significant beneficial ownership by an institutional investor like Rubric Capital Management may signal confidence in Kiniksa Pharmaceuticals International, plc's long-term prospects.

Future Outlook

This Schedule 13G filing is a disclosure of beneficial ownership and does not contain any forward-looking statements or guidance regarding Kiniksa Pharmaceuticals International, plc's future performance or strategic direction.

Management Comments

• Michael Nachmani, Chief Operating Officer of Rubric Capital Management LP, certified that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing the control of the issuer.

Industry Context

This filing is a standard regulatory disclosure of institutional ownership and does not provide specific insights into broader industry trends or competitive landscape within the pharmaceutical sector. It primarily reflects an investment firm's position in a publicly traded company.

Related Party Transactions

• Rubric Capital Master Fund LP, which is a Rubric Fund, has the right to receive or direct the receipt of dividends or proceeds from the sale of more than 5% of the Class A Ordinary Shares. This indicates a related entity to the primary reporting persons holds a significant interest.

Stakeholder Impact

• Shareholders: Provides transparency regarding significant institutional ownership, which can influence market perception and liquidity.
• Investment Professionals: Offers insight into the holdings of a notable investment firm, potentially influencing investment decisions.

Key Dates

Keywords

Kiniksa Pharmaceuticals, Rubric Capital Management, David Rosen, Beneficial Ownership, SEC Filing, Schedule 13G, Class A Ordinary Shares, Institutional Investor, Shareholding